01882nas a2200229   4500000000100000008004100001260004600042653002400088653001600112100001100128700001000139700000900149700000900158700001100167700001100178245003400189856009100223300001000314490000600324520129700330022002501627       2022                            d  bOvid Technologies (Wolters Kluwer Health)10aInfectious Diseases10aDermatology1 aWang L1 aSun P1 aYu M1 aGu H1 aWang H1 aChen X00aLeprosy Update in China, 2019  uhttps://journals.lww.com/ijdv/Fulltext/2022/03000/Leprosy_Update_in_China,_2019.3.aspx  a15-190 v53 a<h3>Objective:&nbsp;</h3>

<p>To study the epidemiology of&nbsp;leprosy&nbsp;in China in 2019 and give suggestions to improve future&nbsp;leprosy&nbsp;control activities.</p>

<h3>Methods:&nbsp;</h3>

<p>We collected&nbsp;leprosy&nbsp;data from the&nbsp;Leprosy&nbsp;Management Information System in China, which includes data from 31 Chinese provinces, autonomous regions, and municipalities, except for Hong Kong, Macao, and Taiwan. We then performed a descriptive analysis of these data.</p>

<h3>Results:&nbsp;</h3>

<p>A total of 464 new&nbsp;leprosy&nbsp;cases were reported nationwide in 2019, with a case detection rate of 0.033/100,000. The proportions of children younger than 15years, multibacillary cases, and cases with World Health Organization grade 2 disability were 1.3%, 90.3%, and 21.6%, respectively. A total of 2,219&nbsp;leprosy&nbsp;cases were registered in China by the end of 2019, giving a prevalence rate of 0.158/100,000. Fifty-six counties had a prevalence rate of more than 1/100,000, and most of them were located in Southwest China. There were 31 reported relapse cases.</p>

<h3>Conclusion:&nbsp;</h3>

<p>The prevalence of&nbsp;leprosy&nbsp;has improved continuously throughout China, but the southwest region is still an area of concern.</p>
  a2096-5540, 2641-8746